No divident + Callenges = SELL

Who will be attending the AGM this Thur (25/4) ? Please share. thanks...

@TheAlphaTrader Your dream is coming
https://klse.i3investor.com/web/blog/detail/thealphatrader/2023-12-08-story-h-213181011-AWC_BHD_7579_A_STOCK_WITH_POSITIVE_DIVERGENCE

Drop so much ? time to fly back .....

https://theedgemalaysia.com/node/688765

Think about, it looks like all man in the street also know givernment will allow to increase price. do you still think there are any meat for late comers ?

looks like the real wolf is coming this time

Game over. Bye

It is TODAY !!!

Bro, it is not old news. It is additional confirmed acquisition.
https://ceomorningbrief.theedgemalaysia.com/article/2023/0649/Home/15/685398

What u are trying to tell the MSM shareholders here ?

Let's do some maths. We just take management guidande of RM10mil PBT this year, and after excluding those one-off corporate expenses (it was recorded at some RM5 mil in 1H2023), we can derive a PBT of RM15mil or PAT of RM12mil in FY2024. Given enlarged share capital of 350mil now, its estimated EPS would be 3.43sen. Let's take PE valuation of 15x (mirror with MYEG), we could justify its fair value of RM0.51. Again, if you look from balance sheet strength (which is not meaningfull in tech stock), it PB is 3.46x (NA of RM0.13 vs market price of RM0.45), which to me, still "ok".
In conclude, current share price is rather "fair" and potentail upside be beyond FY2024 where its profit could be growing another 50% toward RM20mil, then its valuation could jump toward RM0.86! (potentail more than 90% gain from current value of RM0.45)

Wintogether, I guess both of you and Speakup are the same connected person. Same to you too.

Speakup, please dont be so naive and make yourself fool here.

it comes finally....

Declared 11 sen dividend

Unconfirmed source : it is some other big planter is buying up the BPlant stake at RM1.20 from LTAT & Boustead. It is not privatisation deal. So, Still can speculate at current price

https://klse.i3investor.com/web/staticfile/view/502777

"We still like Bermaz Auto, as we expect its sales volume to grow by 11% YoY in FY24 (Apr), driven by: i) Lower Mazda CX-30 prices, thanks to its local assembly; and ii) volume growth for Kia and Peugeot, from a low base. We also like its 9% FY24 yield, and think it may close 4Q23 (results scheduled for 12 Jun) with a special dividend." (Source : RHB Research on 2/6)

Bauto will release its quarterly result on 12Jun, expect another special dividend too

bulk purchase only can get discount. 80sen is coming

Buy on rumours SELL on fact ! Bye Bye my Star

refer to Warran Buffett's advise.....

According to CIMB research today (18/4), it affirms its target price of RM0.86... A MAX upgrade. The report also hints "A potential re-rating catalyst is privatisations in the media sector boosting interest in Astro" ! Collect now before too late

Its CASH PER SHARE already hit 50sen. With its NTA of 90sen + most of its properties are bought inlong long time ago and witout any revaluation. Privatisation is the best move to gain the most. With current share price of < 50sen, it will sure move toward its NTA of 90sen anytime soon

Time to "Salute" it !

anohter TopGlove pattern ?

It is almost certain that BAUTO can repeat its 3Q results in the coming final quarter, due to the 6-mth back log order. Let's play some math, its 3Q report a PAT of RM87mil or EPS of 7.5sen, Accumulated 3Q results already hit RM203mil or EPS of 17.47sen. So, its full year profit could easily hit RM290mil or EPS of 25sen. If u factor in PE 10x only value at RM2.50 or RM3 if u value at PE12x. Dont forget mgt has indicated to declared much higher dividend in 4th quarter. Conclusion : still attractive at current level

Anybody attend the AGM next week ?

https://www.freemalaysiatoday.com/category/highlight/2023/03/10/astro-dismisses-privatisation-speculation-amid-stock-rally/

The below news enough to "kill" the share price
https://www.furnituretoday.com/industry-news/vietnams-wood-furniture-exports-plunge-34/

https://whytoocare-y2k.blogspot.com/

https://www.thestar.com.my/business/business-news/2023/01/30/shopee-to-increase-investments-in-malaysia

Honestly, if just analyse from the impact from the JPJ road tax / driving license issues, I don'y see any fundamental / financial impact to MYEG. In fact, the road tax "delivery" services are actually a "loss making" segment in MYEG !
Of course, sentimental may be affected from speculating that all gov services will be "taken out". But again, MYEG future growth is on the blockchain and overseas business. Its bunisess is rather diversified now. I merely comment on its business / fundamental perceptive.
Assume my above point stands, the plunge in share price is a "de-valuation" process to a more reasonable level. Let's play some maths. Assume its quarterly EPS of 1sen, which translates to 4sen per year (exclude those 1 off gain and be more conservative), its current PE valuation is about 15x, which is fair (or even low) under current market condition.

the next issue to shot will be.......JPJ !

air kosong pun tak ada

Never too late t.o buy now !

this should be a good news : https://www.theedgemarkets.com/node/653330

Time to re-look this counter. Despite rather challenging outlook, I believe the share prices had reflected the low valuation. Any major correction is unlikely. Poh Huat managed to record another historical quarterly (and yearly) sales and profits in its latest 4th quarter reports. Cash and short term investments per share has achieved more than 90sen (take note : the company has no bank borrowings; lease liabilities are merely meaningless accounting entries). However, i really can't quantity its upside as general furniture industry valuation remain low.

If we read through major research report commanding on Bauto target price, it range from RM2.05 to RM2.80. (TA: 2.05; CIMB:2.80; AM: 2.25; HL:RM2.35; Ken:2.65; Rakuten:2.65; RHB:2.55; PBB: 2.65). So, exclude the highest and lowest target price, the average is RM2.44, with average PE of 13x. Assuming a consistent 13sen per year, yield is attractive at 5.9%.

Just do a simple calculation. Given the 1H EPS of 9.97 sen, we assume full year of 20sen moving into FY2023 / 2024. At PE of 15x will have target of RM3.00

Source : https://klse.i3investor.com/web/blog/detail/taresearch/2022-11-25-story-h-304759599-Supercomnet_Technologies_Berhad_Growth_Mostly_Intact

Refer my earlier comments on 23/11, TA research share the similar profit outlook for this year, reporting a profit of RM37mil (Vs TA of RM38.2mil). Moving forward, the profit is expect to DOUBLE from RM25mil in FY21 to RM53.7mil in FY23 (vs my own forecast of RM60mil). Given our current stake of economic of increasing inflationary trend together with risk of technical recession world-wide, SCOMNET is a company that you cannot ignore if you are looking for growing stock. (However, it is NOT for dividend yield investor)
Further, I believe its transfer to Main Board should be completed by Jan next year. By then, many institutions will be grapping this stock. Currently, we get to know that Pheim has started to grab the stock. Others will follow soon by end of Jan next year.
Moving forward in FY23, the growth catalysts are new mass production of IHS; Auto segment will grow by 60% from its Peugeot's fuel tanks and wire harness; the completion expansion of its factory size (by additional 990 sq m).
If you are looking beyond FY2023, then we should expect the raw material disruption should be minimal and the further factory expansion (take 3 years to complete) to increase its floor space by 2400 sq meter). Last and not least, they are looking for more M&A activities. It was not disclosed specifically, but my guess should be its automotive segment in EV where it requires lots of special type of wire. Other future new product launching could be too early to comment.....Its new products include Plass Rescue Occluder (pending FDA approval), Hemodialysis-Vascular-Catheters, AMBU GI SCOPE.

https://www.thestar.com.my/business/business-news/2022/11/25/pheim-asset-management-buys-stake-in-scomnet

Bye bye guys.....

Sources : https://whytoocare-y2k.blogspot.com/2022/11/sep-2022.html

虾皮的业务属于高营业额，但盈利率会来得低。最高峰的员工数目有一千五百人，现在缩小规模到九百人。虽然这个顾客减少了四成的员工，但其他新顾客/工程已成功填补一些岗位。最新总员工数目是3,500人（2022 Nov）。
2022 Nov = 3500（-290）@ -118-290 = -408
2022 June = 3790（-118）
2021 Nov = 3908（+588）@ 912+588 = 1,500
2021 June= 3320（+912）
2020 June= 2408

In short, during AGM, they have confirmed the news of Shopee retrenchment from 1500 to 900. But, management stress that the vacancies has been fill up by other business. As for as I understand his personality, he is not a "bull-shit" type people. I still can trust his statement / comments. As long as they can declare 7-8sen dividend per year, I think we can hold on and ride through the challenges with him. Again, investing in SCICOM is not for growth, but more on yield and suitability / resilience.

SCOMNET growth driver is just started ! Its 9-month results had achieved RM27mil (or EPS of 3.6 sen). Further assume its final quarter to achieve RM10mil (which is prudent), FY2022 full year profit could hit RM37mil or EPS of 5sen.
This is just started, given its new medical products are starting into mass production, this together with its surprising good growth in its auto segment, we can expect its profit to increase by at least 50% from FY2022 toward PAT of RM60mil or EPS of 8sen. Given the industry forward PE of 30x (under bearish condition), this translate into TP of RMRM2.40 ! (this is also its previous high achieved in Nov2020 (around RM2.30)

Supercomnet continued with its momentum of growth by recording its highest ever quarterly net profit of RM10.1 mil, which is a 44.4% increase from the same period of the previous year for the third quarter. This was achieved on the back of a 40.6% jump in revenue to RM45.14 mil. The stellar results were registered due to contributions from its new and existing clients, and a favourable foreign exchange rate. Thus, for the nine-month period to Sep 30, 2022, net profit is now up by 55.6% to RM26.9 mil, on the back of a 18.1% jump in revenue to RM120.98 mil.
For the quarter under review, all three segments recorded an improved revenue performance as compared to the last corresponding period. The medical segment continues to be a key contributor for the Group with a revenue contribution of 56% as compared to 71% in the last corresponding period. Continuing from the previous quarter, the automotive segment continued with its momentum. It recorded a higher revenue contribution at 14%, compared to 10% in the previous period. Revenue contribution for the industrial segment also increased to 30%, compared to 19% in the previous period.
Backed by our growing financial position, Scomnet is on the lookout for earnings accretive mergers and acquisition in the medical segment. Looking ahead, we are confident and optimistic with the group’s mid to long term prospects underpinned by continuous growing demand from customers in addition to several new products in the pipeline. The medical segment will continue to be our main driver, but as you can see, the automotive segment has also picked up. It will be providing some exciting growth and new opportunities in the future.

Don't expect fantastic growth. Only to those dividend collector or temp parking port in view of many uncertainties surrounding. So, assume at 8 sen per year (which the company never fail to pay dividend quarterly since listing), a rather attractive 7.7% yield is expected

@pang72, too bad...no more "dip"

The immediate TP is between RM1.90 to RM2.00. The "boost" here is after the 3q results announcement by 30Nov and transfer to Main Board (dont know when loh)

Extract from TA Research :
Robust Earnings Growth. We estimate Scomnet to register a profit growth of 51.5%40.6%/22.7% in FY22/FY23/FY24 driven by existing orders from Edward Lifesciences and Ambu. In addition, strong demand from Mermaid’s declotting device, new orders secured from Stellantis and maiden contribution from IHS are expected to boost earnings significantly over the next 3 years.

Preparing for the Future. To facilitate future growth, the group will proceed with a 5-storey building expansion. The 5-storey building will provide an additional 12,000 sqm and will take about 3 years to complete. The new plant will be GMP compliance and will cater for more medical products.

Transfer of Listing. The group has kicked off the necessary preparations for transfer of listing. We opined that the move will help to lift interest on the stock, especially from institutional funds (below 15% currently).

Reasonable Valuations. Scomnet is currently trading at 26.2x PER. We opine that our target PE of 32.0x is reasonable (in-line with its 5-years mean), considering that the peers are trading at 31-36x.